CD8-Targeted, Integrating Viral Vectors Transduce Resting T Cells and Enable Extracorporeal Delivery (ECD) for Rapid CAR T Cell TherapiesJesse Green, Terry J. Fry, Kutlu G. Elpek et al.|Blood|2022Cited by 5
A Dual-Antigen Targeting, Hypoimmune Allogeneic CAR T to Evade Innate and Adaptive Immune Rejection and Overcome Antigen EscapeAdam Johnson, Aaron E. Foster, Hallee Wright et al.|Blood|2022Cited by 2
BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent Anti-Tumor Activity Together with the Ability to Evade Innate and Adaptive Immune Rejection in Pre-Clinical Tumor ModelsJeremy M. Kinder, Aaron E. Foster, Chanel Athena-Estrada et al.|Blood|2022Cited by 1
Functional T Cell Assays Are Predictive of Pre-Clinical Potency to Generate Allogeneic, Hypoimmune CD19 CAR T CellsDarin Salloum, Aaron E. Foster, Kavita Tundwal et al.|Blood|2022Cited by 0
Abstract LB311: Increased potency of CD8-targeted fusosomes enhances CAR gene delivery to resting primary T cellsJesse Green, Terry J. Fry, Brian Granger et al.|Cancer Research|2023Cited by 0